A therapeutic method of the vendor Mustin response condition in the patient who needs the reduced medication capacity

Japanese Patent JP6224064

B2

Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.

WO/2011/084642	COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES
JP2008517974	Use of dipyridamole for the treatment and prevention of thromboembolic disease in combination with antithrombotic drugs
JP6129211	New curative medicine

Sundalam, Srikans
Tariff, Scott, Elle.

JP2015501814A

November 01, 2017

March 15, 2013

Click for automatic bibliography generation  

Eagle Pharmaceuticals Incorporated

A61K31/4184; A61K9/08; A61K47/02; A61K47/10; A61K47/20; A61P35/00; A61P35/02

JP2013518130A
JP2008505966A

US20110184036
WO2007026771A1

HIGHLIGHT OF PRESCRIBING INFORMATION (TREANDA),2008年,pp.1-11
日本医薬品集 医療薬(2004年度版) ,株式会社じほう ,2003年10月25日,pp.186-188、1089、2298-2299、2421
医薬品添加物事典 2007,株式会社薬事日報社,2007年,pp.242-243、279-280
Haematologica. 2005, Vol.90, No.10, pp.1357-1364
Cancer Sci., 2010,Vol.101,No.9, pp.2054-2058

Yusuke Hiraki
Satoshi Fujita
Eiichi Arai
Natsuo Tanaka
Naoko Kikuta

Previous Patent: A Phosphoji esterase 1-target tracer and a method

Next Patent: UNIDIRECTIONAL MAGNETIC FIELD GENERATOR